// App-Quantinova.ai

2931 : Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in non small cell lung cancer cells with oncogenic EGFR mutation

Researchers

Presenter

  • Nayoung Kim

Principal Investigators

  • Ahye Cho

  • Hideo Watanabe

  • Yoon-La Choi

  • Meraj Aziz

  • Michelle Kassner

  • Je-Gun Joung

  • Angela KJ Park

  • Joshua Francis

  • Joon Seol Bae

  • Soo-min Ahn

  • Kyoung-Mee Kim

  • Joon-Oh Park

  • Woong-Yang Park

  • Myung-Ju Ahn

  • Keunchil Park

  • Hongwei Holly Yin

  • Jeonghee Cho

Medical Centers

  • Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, New York, NY

  • Cancer and Cell Biology Division, The Translational Genomics Research Institute (TGen), Phoenix, AZ

  • Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Secernin 1

  • PI3K/AKT

Drug/Treatment

  • Erlotinib hydrochloride

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved